visceral adipose tissue is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2025-10-22. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, built from 44 amino acids. Its sequence follows the natural human GHRH(1-44) backbone, with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification blocks recognition by dipeptidyl peptidase IV, the enzyme that rapidly truncates the native hormone in circulation. The result is a molecule with a substantially longer plasma residence time than unmodified GHRH, which makes it practical for clinical and laboratory study.
Receptor-level activity begins when the peptide binds the GHRH receptor, a class B G-protein-coupled receptor found on pituitary somatotroph cells. Occupancy triggers Gs-mediated activation of adenylyl cyclase and a rise in intracellular cyclic AMP, which in turn promotes synthesis and pulsatile release of growth hormone. Because the compound acts upstream of the growth hormone axis rather than supplying hormone directly, its effect depends on intact pituitary function. Binding studies in cell culture and animal models have established this pathway; the detailed kinetics of receptor recycling in humans remain less well characterized.
tesamorelin 是一种人工合成的四十四肽，序列与内源性生长激素释放激素（GHRH）的 1-44 片段一致，区别在于 N 端加接了一个反式-3-己烯酰基。该修饰抑制二肽基肽酶 IV 的快速切割，从而延长分子在循环中的存留时间。作为肽类分子，它难以经胃肠道吸收，文献中讨论的均是注射途径。分类上通常把它归为 GHRH 类似物，以区别于生长激素本身。
作用位置在垂体前叶。tesamorelin 与 GHRH 受体结合后激活腺苷酸环化酶，升高细胞内 cAMP，再经蛋白激酶 A 通路促进生长激素的合成与释放。由于它作用于内源调控节点，生长激素仍以脉冲方式分泌，而不是被持续抬升到固定水平。生长激素随后在肝脏等组织诱导胰岛素样生长因子 1 产生，构成完整的生长激素轴响应。
研究背景集中在特定人群的体成分改变，尤其是与脂肪分布异常相关的内脏脂肪堆积。不同地区对它的监管状态与获批适应症并不一致，部分市场仅限特定诊断人群使用。在一般人群中的长期效应、与其他激素的相互作用以及停药后的维持情况仍属开放问题，现有数据不足以给出普遍结论。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | GHRH receptor agonist |
| Residue count | 44 amino acids | Matches human GHRH(1-44) length |
| N-terminal modification | trans-3-hexenoyl group | Confers resistance to dipeptidyl peptidase IV |
| Appearance | White to off-white powder | Typically supplied lyophilized in a sealed vial |
| Solubility class | Freely soluble in water | Hydrophilic peptide; polar solvent compatible |
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Binding of tesamorelin to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and the release of growth hormone into circulation. Because the peptide acts upstream of the growth hormone axis, its effects are partly mediated by hepatic insulin-like growth factor 1 (IGF-1) production. The pulsatile character of endogenous growth hormone secretion is preserved rather than replaced. Whether amplified signaling produces effects beyond those of native GHRH remains an area of ongoing investigation.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
A Phase 3 program led to regulatory approval in the United States in 2010 for reduction of excess visceral abdominal fat in adults with HIV and lipodystrophy. Subsequent studies examined effects on liver fat, muscle area, and metabolic markers, with mixed findings for some endpoints. Long-term cardiovascular outcomes and effects on mortality remain uncertain because most trials were relatively short and focused on imaging-based fat measurements. Use in populations without HIV has been studied experimentally but is not part of the approved indication.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
After injection, the peptide binds receptors on somatotroph cells in the anterior pituitary. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone into the bloodstream. Because the compound works through the body's own regulatory system, growth hormone pulses retain much of their normal feedback control. Repeated administration also raises insulin-like growth factor 1, a hormone produced mainly in the liver. Investigators treat that rise as a marker that the pituitary axis has been engaged.
Clinical study of tesamorelin has centered on adults with HIV-associated lipodystrophy, a condition in which abdominal fat accumulates while peripheral fat is lost. In controlled trials, treated participants showed reductions in visceral adipose tissue measured by imaging, alongside modest shifts in some lipid values. Effects on subcutaneous fat were smaller and less consistent across studies. Whether these changes translate into fewer cardiovascular events remains an open question, because the trials were not designed or powered to answer it.
Tesamorelin is a synthetic peptide that acts as an analog of growth hormone-releasing hormone, a natural hypothalamic signal. Its sequence corresponds to the forty-four amino acid form of the human hormone, with a small acyl group attached near the amino terminus. That modification slows enzymatic breakdown and extends the time the peptide remains active in circulation. The compound was developed as a pharmacological way to raise endogenous growth hormone output rather than supplying the hormone directly.
The AQSIQ announced on 5 October that all tests showed all milk produced after 14 September were free from contamination. The General Administration of Quality Supervision, Inspection and Quarantine stated all dairy products made before 14 September will be tested for melamine. They gave notice to all supermarkets, shops, and all city, town and village-level vendors to urgently remove and seal up all powdered milk and liquid milk made before 14 September, pending further testing. Five government agencies, including the Ministry of Health, issued a joint statement on 9 October setting the legally acceptable level of melamine content in infant formula at 1 ppm (1 mg/kg), and at 2.5ppm in other dairy products (including milk) - in line with standards recognised by the World Health Organization and the UN Food and Agriculture Organization. A researcher at the Chinese Centre for Disease Control and Prevention said that any amount exceeding 1 ppm would give reason to suspect its presence was intentional.
However, the Nomenclature of Steroids recommends the locant of a double bond to be always adjacent to the syllable designating the unsaturation, therefore, having it as a suffix rather than a prefix, and without the use of the Δ character, i.e. pregn-4-ene-11β,17α-diol-3,20-dione or androst-4-ene-3,11,17-trione. The double bond is designated by the lower-numbered carbon atom, i.e. "Δ4-" or "4-ene" means the double bond between positions 4 and 5. The saturation of carbons of a parent steroid can be done by adding "dihydro-" prefix, i.e., a saturation of carbons 4 and 5 of testosterone with two hydrogen atoms is 4,5α-dihydrotestosterone or 4,5β-dihydrotestosterone. Generally, when there is no ambiguity, one number of a hydrogen position from a steroid with a saturated bond may be omitted, leaving only the position of the second hydrogen atom, e.g., 5α-dihydrotestosterone or 5β-dihydrotestosterone. The Δ5-steroids are those with a double bond between carbons 5 and 6 and the Δ4 steroids are those with a double bond between carbons 4 and 5. The abbreviations like "P4" for progesterone and "A4" for androstenedione for refer to Δ4-steroids, while "P5" for pregnenolone and "A5" for androstenediol refer to Δ5-steroids. The suffix -ol denotes a hydroxy group, while the suffix -one denotes an oxo group. When two or three identical groups are attached to the base structure at different positions, the suffix is indicated as -diol or -triol for hydroxy, and -dione or -trione for oxo groups, respectively.
=== Foreign policy === Moore supports Israel's right to defend itself and a two-state solution to the Israeli–Palestinian conflict. In December 2022, he attended the Jewish Community Relations Council of Greater Washington's legislative breakfast, where he said he would be "very aggressive" in promoting trade between Maryland and Israel and promised that one of his first overseas visits would be to Israel. He expressed solidarity with Israel amid the October 7 attacks, and later supported an immediate ceasefire in the Gaza war. In October 2024, Moore criticized a Students for Justice in Palestine event at the University of Maryland, College Park held on the one-year anniversary of the October 7 attack to honor Palestinian civilians killed in the Gaza war, saying that he felt that it was an "inappropriate date for such an event". In May 2026, Moore told Politico that he believed Israeli Prime Minister Benjamin Netanyahu had committed war crimes in the Gaza war, citing his use of food as a negotiating tool. In April 2026, Moore criticized U.S. involvement in the 2026 Iran war, likening it to the war in Afghanistan and fearing it would evolve into "another forever war". He also criticized President Donald Trump for not clearly addressing the American people on what the U.S. is doing in Iran or what success looks like.
Sources: en.wikipedia.org
=== Lithium-air battery === Among many advanced electrochemical energy storage devices, rechargeable lithium-air batteries are of particular interest due to their considerable energy storing capacities and high power densities. As the battery is being used, lithium ions combine with oxygen from the air to form particles of lithium oxides, which attach to carbon fibers on the electrode. During recharging, the lithium oxides separate again into lithium and oxygen which is released back into the atmosphere. This conversion sequence is highly inefficient because there is significant voltage difference of more than 1.2 volts between the output voltage and the charging voltage of the battery meaning that approximately 30% of the electrical energy is lost as heat when the battery is charging. Also the large volume changes resulting from continuous conversion of oxygen between its gaseous and solid state puts stress on the electrode and limits its lifetime.
== Function == This protein is a member of the serpin superfamily of serine proteinase inhibitors. Its expression is induced by heat shock. HSP47 is expressed in the endoplasmic reticulum. These cells synthesize and secrete type I and type II collagen. The protein localizes to the endoplasmic reticulum lumen and binds collagen; thus it is thought to be a molecular chaperone involved in the maturation of collagen molecules. HSP47 is essential for the correct folding of procollagen. Antibodies directed to this protein have been found in patients with rheumatoid arthritis.
=== Agriculture === Applying polyamines such as putrescine (PUT) to a plant causes lowered ethylene production. When applied pre-harvest, it increases plant resistance to high temperatures and drought. When applied post-harvest (to the fruits), PUT delays the ripening process and extends the shelf life. It is known to be applicable to a wide variety of fruits, including but not limited to peach, plum, cherry, tomato, and pear. It is also applicable to other edible parts such as broccoli. PUT has an all-round effect: it delays the deterioration of appearance (weight [mainly water] loss, % of rotten fruits, firmness), taste (total soluble solids, titratable acidity, organic acid content), and nutrition (phenol content, antioxidant content). A nanoparticle of putrescine coated with chitosan has been used as an edible coating on strawberries. Like regular putrescine treatment, treated fruits had higher antioxidant capacity, higher enzyme activities, higher tissue firmness, and higher total soluble solids. It extends the post-harvest life of strawberries during storage up to 12 days.
Sources: en.wikipedia.org
Chelation therapy is a form of medical treatment in which a chelating ligand is used to selectively remove a metal from the body. When the metal exists as a divalent ion, such as with lead, Pb2+ or mercury, Hg2+ selectivity against calcium, Ca2+ and magnesium, Mg2+, is essential in order that the treatment does not remove essential metals. Selectivity is determined by various factors. In the case of iron overload, which may occur in individuals with β-thalessemia who have received blood transfusions, the target metal ion is in the +3 oxidation state and so forms stronger complexes than the divalent ions. It also forms stronger complexes with oxygen-donor ligands than with nitrogen-donor ligands. deferoxamine, a naturally occurring siderophore produced by the actinobacter Streptomyces pilosus and was used initially as a chelation therapy agent. Synthetic siderophores such as deferiprone and deferasirox have been developed, using the known structure of deferoxamine as a starting point. Chelation occurs with the two oxygen atoms. Wilson's disease is caused by a defect in copper metabolism which results in accumulation of copper metal in various organs of the body. The target ion in this case is divalent, Cu2+. This ion is classified as borderline in the scheme of Ahrland, Chatt and Davies. This means that it forms roughly equally strong complexes with ligands whose donor atoms are N, O or F as with ligands whose donor atoms are P, S or Cl.
== Description == The neon tetra has a light-blue back over a silver-white abdomen. The fish is characterized by a bright iridescent blue horizontal stripe along each side of the fish from its nose to the base of the adipose fin, and an iridescent red stripe that begins at the middle of the body and extends posteriorly to the base of the caudal fin. The fish is partially transparent (including fins) except for these markings. Sexual dimorphism is slight, with the female having a slightly larger belly, and a bent iridescent stripe rather than the male's straight stripe. During the night, the blue and red become gray or black as the fish rests. It reactivates once it becomes active in the morning. This peculiar change is due to the neon tetras capacity to change the color of its iridescent stripe in response to lighting conditions. In a light-adapted state it is blue-green, likewise in a dark-adapted state its color changes to indigo. This change is produced by guanine crystals in their cells that reflect light. The neon tetra grows to approximately 4 cm (1.6 in) in overall length.
A person with diabulimia, especially if not treated early, can result in negative effects on the body. Of diabetics who have a DEB, some intentionally misuse insulin to control weight. This may also involve irregular eating patterns. Suspension of insulin combined with overeating can result in ketoacidosis. Multiple hospitalizations for ketoacidosis or hyperglycemia are cues to screen for an underlying emotional conflict.
=== Location === Ghrelin cells are found mainly in the stomach and duodenum, but also in the jejunum, lungs, pancreatic islets, gonads, adrenal cortex, placenta, and kidney. It has also been shown that ghrelin is produced locally in the brain. Additionally, research suggests that ghrelin may be produced in the myocardium and have an 'autocrine/ paracrine' like effect within the heart. Ghrelin cells are also found in oxyntic glands (20% of cells), pyloric glands, and small intestine.
Sources: en.wikipedia.org
The principal difference is a chemical cap on the N-terminal tyrosine that prevents rapid enzymatic cleavage. Native GHRH is degraded within minutes in plasma, whereas the modified peptide persists considerably longer. The amino acid backbone otherwise mirrors the natural hormone.
No. It is a receptor agonist that stimulates the pituitary to release endogenous growth hormone. It does not contain or deliver growth hormone. Its downstream effects therefore depend on a functioning pituitary and an intact signaling pathway.
Pituitary responsiveness, receptor availability, and the natural pulsatility of the growth hormone axis all contribute. Because the compound amplifies an existing release pattern rather than overriding it, timing and physiological state matter. Individual variability in response is well documented but not fully explained.
tesamorelin 属 GHRH 类似物，作用于垂体受体以促进内源生长激素释放；生长激素本身是直接补充的外源激素。两者在给药逻辑、作用位点和反馈调控路径上并不相同。